Friday 6/14 Insider Buying Report: KIRK, DSSI (Nasdaq.com)
On Wednesday, Kirkland’s (KIRK)’s Director, Charles Pleas III, made a $239,000 purchase of KIRK, buying 100,000 shares at a cost of $2.39 each. Kirkland’s is trading down about 5.2% on the day Friday. This buy marks the first one filed by Pleas III in the past twelve months. And on Tuesday, CEO Craig H. Stevenson Jr. purchased $236,485 worth of Diamond S Shipping (DSSI), purchasing 20,231 shares at a cost of $11.69 each. Before this latest buy, Stevenson Jr. made one other buy in the past twelve months, purchasing $490,972 shares for a cost of $12.52 a piece. Diamond S Shipping is trading off about 1.6% on the day Friday. Bargain hunters have the opportunity to snag DSSI even cheaper than Stevenson Jr. did, with shares changing hands as low as $11.02 at last check today which is 5.7% under Stevenson Jr.’s purchase price.
Sanofi EVP’s Bioverativ Blabbing Ends in Insider Trading Cases (Fierce Pharma)
For Sanofi, snapping up Biogen spinout Bioverativ for $11.6 billion bolstered its rare disease franchise by adding hemophilia drugs Eloctate and Alprolix. But for a Swiss man, catching an early whiff of the deal has allegedly brought some illegal gains—and now, a civil and a criminal case in the U.S. Roland Mathys, 32, is charged with insider trading before Sanofi’s Bioverativ acquisition, U.S. prosecutors unveiled Thursday. Using nonpublic information from a Sanofi executive vice president, the Swiss businessman allegedly bought 1,607 Bioverativ call options over a week in January 2018 and profited more than $4.7 million after the company’s stock soared at the official acquisition news later that month.
Abu Dhabi Securities Exchange Insider’s Trading Ban Starts June 16 (Zawya)
Abu Dhabi – The Abu Dhabi Securities Exchange (ADX) announced that the insider’s trading prohibition period will start as of Sunday, 16 June 2019 until the full disclosure of financial statements for the second quarter of the year. All listed-firms and departments at the ADX and all brokers accredited by the stock market, as well as investors in the market, will be subject to this resolution, according to a statement. In a separate statement, the ADX highlighted that listed-companies shall provide a reviewed quarterly financial report within a 45-day period from the end of any quarter along with the board’s report or management discussion and analysis.
A Director at Sharps Compliance Corp (NASDAQ: SMED) is Buying Shares (Analyst Ratings)
Today, a Director at Sharps Compliance Corp (SMED), Parris Holmes, bought shares of SMED for $132.3K. Following this transaction Parris Holmes’ holding in the company was increased by 4.43% to a total of $3.21 million. Based on Sharps Compliance Corp’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $9.45 million and GAAP net loss of $1.13 million. In comparison, last year the company earned revenue of $9.43 million and had a GAAP net loss of $757K. Currently, Sharps Compliance Corp has an average volume of 6,953.
New York U.S. Attorney: Swiss Man Charged in Manhattan Federal Court For Insider Trading Scheme That Generated More Than $4.7M in Profits (Market Screener)
NEW YORK, June 13 — The U.S. Attorney for the Southern District of New York, Geoffrey S. Berman, issued the following news release: Geoffrey S. Berman, the United States Attorney for the Southern District of New York, and William F. Sweeney Jr., the Assistant Director-in-Charge of the New York Field Office of the Federal Bureau of Investigation (“FBI”), announced today the indictment of ROLAND MATHYS for his participation in a scheme to trade on material, nonpublic information (the “Inside Information”) regarding a tender offer by Sanofi, S.A (“Sanofi”) for Bioverativ, Inc. (“Bioverativ”). After the tender offer was announced, MATHYS’s trading yielded over $4.7 million in illegal profits.
Mario J. Gabelli Purchases 5,000 Shares of Gabelli Global Small Md Cp Vl Trst (NYSE:GGZ) Stock (Tech Know Bits)
Gabelli Global Small Md Cp Vl Trst (NYSE:GGZ) insider Mario J. Gabelli acquired 5,000 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were bought at an average price of $11.55 per share, for a total transaction of $57,750.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission.
